Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Klaus

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Applied and Environmental Microbiology|October 3, 2020
Burkholderia thailandensis Methylated Hydroxyalkylquinolines: Biosynthesis and Antimicrobial Activity in CoculturesJennifer R Klaus, Charlotte Majerczyk, Stephanie Moon, et al.
Plos One|December 11, 2014
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin LymphomasSarah K Knutson, Natalie M Warholic, L Danielle Johnston, et al.
Blood|June 27, 2013
Potent inhibition of DOT1L as treatment of MLL-fusion leukemiaScott R Daigle, Edward J Olhava, Carly A Therkelsen, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo ActivityJohn E Campbell, Kevin W Kuntz, Sarah K Knutson, et al.
Nature Communications|November 13, 2024
Whole genome CRISPRi screening identifies druggable vulnerabilities in an isoniazid resistant strain of Mycobacterium tuberculosisXinYue Wang, William J Jowsey, Chen-Yi Cheung, et al.
Biopharmaceutics & Drug Disposition|January 14, 2014
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitorAravind Basavapathruni, Edward J Olhava, Scott R Daigle, et al.
Journal of Medicinal Chemistry|June 26, 2024
Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell LymphomaMatthew M Weiss, Xiaozhang Zheng, Nan Ji, et al.
Nature Chemical Biology|October 2, 2012
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsSarah K Knutson, Tim J Wigle, Natalie M Warholic, et al.
Journal of Medicinal Chemistry|August 16, 2024
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune DiseasesXiaozhang Zheng, Nan Ji, Veronica Campbell, et al.
Molecular Cancer Therapeutics|February 25, 2014
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphomaSarah K Knutson, Satoshi Kawano, Yukinori Minoshima, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Applied and Environmental Microbiology|October 3, 2020
Burkholderia thailandensis Methylated Hydroxyalkylquinolines: Biosynthesis and Antimicrobial Activity in CoculturesJennifer R Klaus, Charlotte Majerczyk, Stephanie Moon, et al.
Plos One|December 11, 2014
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin LymphomasSarah K Knutson, Natalie M Warholic, L Danielle Johnston, et al.
Blood|June 27, 2013
Potent inhibition of DOT1L as treatment of MLL-fusion leukemiaScott R Daigle, Edward J Olhava, Carly A Therkelsen, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo ActivityJohn E Campbell, Kevin W Kuntz, Sarah K Knutson, et al.
Nature Communications|November 13, 2024
Whole genome CRISPRi screening identifies druggable vulnerabilities in an isoniazid resistant strain of Mycobacterium tuberculosisXinYue Wang, William J Jowsey, Chen-Yi Cheung, et al.
Biopharmaceutics & Drug Disposition|January 14, 2014
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitorAravind Basavapathruni, Edward J Olhava, Scott R Daigle, et al.
Journal of Medicinal Chemistry|June 26, 2024
Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell LymphomaMatthew M Weiss, Xiaozhang Zheng, Nan Ji, et al.
Nature Chemical Biology|October 2, 2012
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsSarah K Knutson, Tim J Wigle, Natalie M Warholic, et al.
Journal of Medicinal Chemistry|August 16, 2024
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune DiseasesXiaozhang Zheng, Nan Ji, Veronica Campbell, et al.
Molecular Cancer Therapeutics|February 25, 2014
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphomaSarah K Knutson, Satoshi Kawano, Yukinori Minoshima, et al.
Pageof 5